Dodge & Cox Biomarin Pharmaceutical Inc Transaction History

Dodge & Cox

$164 Billion
Q1 2025

A detailed history of Dodge & Cox transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Dodge & Cox holds 14,955,240 shares of BMRN stock, worth $888 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares

14,955,240

Previous 14,746,235 1.42%

Holding current value

$888 Million

Previous $969 Million 9.07%

% of portfolio

0.65%

Previous 0.61%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$61.25 - $72.83 $12.8 Million - $15.2 Million	209,005 Added 1.42%	14,955,240 $1.06 Billion
Q4 2024 Feb 13, 2025	BUY	$61.93 - $70.49 $52.5 Million - $59.8 Million	847,917 Added 6.1%	14,746,235 $969 Million
Q3 2024 Nov 13, 2024	SELL	$69.02 - $93.84 $2.22 Million - $3.02 Million	-32,175 Reduced 0.23%	13,898,318 $977 Million
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $4.65 Million - $5.76 Million	-62,450 Reduced 0.45%	13,930,493 $1.15 Billion
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $93,867 - $110,880	-1,120 Reduced 0.01%	13,992,943 $1.22 Billion
Q4 2023 Feb 15, 2024	SELL	$76.22 - $98.51 $12.2 Million - $15.7 Million	-159,440 Reduced 1.13%	13,994,063 $1.35 Billion
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $11.6 Million - $12.9 Million	-136,800 Reduced 0.96%	14,153,503 $1.25 Billion
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $3.38 Million - $3.91 Million	-39,010 Reduced 0.27%	14,290,303 $1.24 Billion
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $4.77 Million - $6.37 Million	-54,350 Reduced 0.38%	14,329,313 $1.39 Billion
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $31.6 Million - $42.4 Million	-390,300 Reduced 2.64%	14,383,663 $1.49 Billion
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $19.2 Million - $22.6 Million	-233,100 Reduced 1.55%	14,773,963 $1.25 Billion
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $2 Million - $2.43 Million	-27,936 Reduced 0.19%	15,007,063 $1.24 Billion
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $15.6 Million - $19.5 Million	209,950 Added 1.42%	15,034,999 $1.16 Billion
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $463,813 - $591,536	6,467 Added 0.04%	14,825,049 $1.31 Billion
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $53.6 Million - $61.2 Million	716,485 Added 5.08%	14,818,582 $1.15 Billion
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $170 Million - $191 Million	2,247,789 Added 18.96%	14,102,097 $1.18 Billion
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $154 Million - $187 Million	2,057,384 Added 21.0%	11,854,308 $895 Million
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $151 Million - $187 Million	2,076,701 Added 26.9%	9,796,924 $859 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $295 Million - $538 Million	4,104,483 Added 113.52%	7,720,223 $587 Million
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $26 Million - $40.6 Million	-326,768 Reduced 8.29%	3,615,740 $446 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $31.9 Million - $43.3 Million	-447,007 Reduced 10.18%	3,942,508 $333 Million
Q4 2019 Feb 13, 2020	BUY	$64.27 - $86.37 $282 Million - $379 Million	4,389,515 New	4,389,515 $371 Million

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.

Account